Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Narra X
Galo Farfán-Cano
Society of Infectious Diseases of Guayas, Guayaquil, Ecuador; Rey Juan Carlos University, Madrid, Spain; School of Medicine, University of Guayaquil, Guayaquil, Ecuador; Teaching and Research Sub-directorate, Northern of Guayaquil General Hospital "L
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Physics Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Achromobacter xylosoxidans as emerging pathogen in healthcare settings: A mini review Galo Farfán-Cano; Glen A. Silva-Rojas
Narra X Vol. 1 No. 1 (2023): April 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v1i1.74

Abstract

Microorganisms of the genus Achromobacter have been mentioned as a cause of opportunistic infections, mainly in patients with cystic fibrosis or pulmonary lymphoma, with the species Achromobacter xylosoxidans being identified to a large extent. A. xylosoxidans was first described in 1971 and is an opportunistic pathogen. However, it been reported to cause chronic purulent otitis, meningitis, pneumonia, peritonitis and urinary tract infections, chronic obstructive pulmonary disease and other infections. The present literature review aims to analyze and synthesize the state of the art on A. xylosoxidans and its potential as an emerging pathogen in the healthcare settings. We discuss A. xylosoxidans as an emerging opportunistic pathogen that is associated with healthcare infections. This review further discusses the prevalence of A. xylosoxidans in healthcare settings, the types of infections it can cause, and the risk factors for acquiring an A. xylosoxidans infection. The review also covers the challenges in treating A. xylosoxidans infections, including its potential for drug resistance and the lack of specific treatments. Strategies for preventing and controlling A. xylosoxidans infections in healthcare settings were also discussed.
Co-Authors Glen A. Silva-Rojas